Investigational Site Number : 2500002

Créteil 94010

2 studies enrolling now · 3 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Sickle Cell Disease, Transplant Rejection

Studies at this site

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) — Running, not enrolling